Macrophage CCL7 Drives Colorectal Cancer Immunotherapy Resistance by Modulating Macrophage and CD8⁺ T Cell Infiltration

Although immune checkpoint inhibitors (ICIs) have emerged as a transformative approach in cancer immunotherapy, their clinical benefit in colorectal cancer (CRC) remains modest. Elucidating the mechanisms that underlie resistance to ICIs in CRC is critical for identifying novel therapeutic targets. To dissect the role of CCL7 in CRC, we employed myeloid-specific Ccl7 knockout mice alongside MC38 tumor-bearing models. Tumor tissues were analyzed using proteomics, RNA sequencing, and flow cytometr